SparingVision’s website
3 known investors
SparingVision is a genomic medicine company developing gene therapies for ophthalmic diseases, including SPVN06, a neuroprotective gene therapy for retinal conditions. Its lead candidate is being evaluated in the PRODYGY clinical trial.
BiotechDeep TechDigital Health